Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $29.0 million.

  • vTv Therapeutics' Total Liabilities rose 1465.29% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year increase of 1465.29%. This contributed to the annual value of $24.0 million for FY2024, which is 1894.68% down from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Total Liabilities is $29.0 million, which was up 1465.29% from $24.0 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Total Liabilities peaked at $29.6 million during Q2 2022, and registered a low of $8.4 million during Q3 2021.
  • Moreover, its 5-year median value for Total Liabilities was $26.0 million (2024), whereas its average is $22.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 4461.2% in 2021, then surged by 23311.03% in 2022.
  • Quarter analysis of 5 years shows vTv Therapeutics' Total Liabilities stood at $10.3 million in 2021, then soared by 167.26% to $27.4 million in 2022, then increased by 7.91% to $29.6 million in 2023, then fell by 18.95% to $24.0 million in 2024, then grew by 20.81% to $29.0 million in 2025.
  • Its last three reported values are $29.0 million in Q3 2025, $24.0 million for Q2 2025, and $23.1 million during Q1 2025.